Ipsen Pharma

Assessment of genetic defects, baseline characteristics and adverse events reported in the Increlex (R) registry (2021) Polak M, Bang P, Perrot V, Sert C, Storr HL, Wölfle J Conference contribution Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria (2021) Rinke A, Maintz C, Muller L, Weber MM, Lahner H, Pavel ME, Saeger W, et al. Journal article Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study (2021) Pavel ME, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results (2021) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Thanh TXM, et al. Conference contribution The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors: Results from phase 3 of the RAISE project (2021) Pavel ME, Dromain C, Ronot M, Schaefer N, Mandair D, Gueguen D, Elvira D, et al. Conference contribution Dissociated response as a new biomarker of treatment response in neuroendocrine tumors: Results from phase 3 of the RAISE project (2021) Dromain C, Pavel ME, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, et al. Conference contribution Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome (2021) Bang P, Wölfle J, Perrot V, Sert C, Polak M Journal article Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (2020) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen (2020) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Xuan-Mai Truong Thanh , et al. Conference contribution Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE (2020) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath , Shah T, Pape UF, Truong Thanh XM, et al. Conference contribution